WO2013106766A3 - Indications thérapeutiques du miarn-1291 - Google Patents

Indications thérapeutiques du miarn-1291 Download PDF

Info

Publication number
WO2013106766A3
WO2013106766A3 PCT/US2013/021307 US2013021307W WO2013106766A3 WO 2013106766 A3 WO2013106766 A3 WO 2013106766A3 US 2013021307 W US2013021307 W US 2013021307W WO 2013106766 A3 WO2013106766 A3 WO 2013106766A3
Authority
WO
WIPO (PCT)
Prior art keywords
mir
methods
therapeutic indications
conditions
human diseases
Prior art date
Application number
PCT/US2013/021307
Other languages
English (en)
Other versions
WO2013106766A2 (fr
Inventor
Aiming Yu
Yuzhuo PAN
Jingxin Qiu
Original Assignee
The Research Foundation Of State University Of New York
Health Research, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Research Foundation Of State University Of New York, Health Research, Inc. filed Critical The Research Foundation Of State University Of New York
Publication of WO2013106766A2 publication Critical patent/WO2013106766A2/fr
Publication of WO2013106766A3 publication Critical patent/WO2013106766A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne dans des compositions et des procédés destinés à la prévention et au traitement de maladies et/ou d'états humain(e)s. La présente invention concerne, entre autres, la reconstitution de niveaux de miARN-1291 dans des échantillons et chez des sujets. Des procédés destinés au diagnostic et au traitement de maladies et d'états humain(e)s par l'évaluation des niveaux d'expression du miARN -1291 sont également décrits. Des procédés de traitement de cancers humains par modification ou régulation des voies du miARN sont également décrits.
PCT/US2013/021307 2012-01-13 2013-01-11 Indications thérapeutiques du miarn-1291 WO2013106766A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261586446P 2012-01-13 2012-01-13
US61/586,446 2012-01-13

Publications (2)

Publication Number Publication Date
WO2013106766A2 WO2013106766A2 (fr) 2013-07-18
WO2013106766A3 true WO2013106766A3 (fr) 2013-09-12

Family

ID=48782096

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/021307 WO2013106766A2 (fr) 2012-01-13 2013-01-11 Indications thérapeutiques du miarn-1291

Country Status (1)

Country Link
WO (1) WO2013106766A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015183667A1 (fr) 2014-05-28 2015-12-03 The Regents Of The University Of California Molecules hybrides d'arnt/pre-miarn et procedes d'utilisation
WO2016153880A2 (fr) 2015-03-23 2016-09-29 The Regents Of The University Of California Procédés pour la détection de l'activité rnase
CN105106959B (zh) * 2015-08-16 2018-07-17 深圳市倍昂生物科技有限公司 虫草素在制备与放疗和/或化疗协同治疗肿瘤的药物中的应用以及一种药物组合物
CA3041761A1 (fr) * 2016-10-31 2018-05-03 Gifu University Molecule d'acide nucleique double brin, et son utilisation
CN113498437A (zh) * 2019-02-26 2021-10-12 首尔大学校产学协力团 包含末端尿苷酰基转移酶4/7表达调控因子的用于预防或治疗癌症的药学组合物
CN114891742A (zh) * 2022-06-23 2022-08-12 杭州中赢生物医疗科技有限公司 一种强杀伤性nk细胞的培养基及体外扩增方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060165659A1 (en) * 2002-11-13 2006-07-27 Carlo Croce Compositions and methods for cancer diagnosis and therapy
US20060189557A1 (en) * 2004-09-02 2006-08-24 Yale University Regulation of oncogenes by microRNAs
WO2009149182A1 (fr) * 2008-06-04 2009-12-10 The Board Of Regents Of The University Of Texas System Modulation de l'expression génique par ciblage d'un petit arn endogène de promoteurs de gènes
KR20100009268A (ko) * 2008-07-18 2010-01-27 국립암센터 마이크로ｒｎａ분자를 포함하는 항암 조성물
WO2010139810A1 (fr) * 2009-06-05 2010-12-09 Febit Holding Gmbh Empreinte de micro-arn utilisée dans le diagnostic du cancer du poumon

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060165659A1 (en) * 2002-11-13 2006-07-27 Carlo Croce Compositions and methods for cancer diagnosis and therapy
US20060189557A1 (en) * 2004-09-02 2006-08-24 Yale University Regulation of oncogenes by microRNAs
WO2009149182A1 (fr) * 2008-06-04 2009-12-10 The Board Of Regents Of The University Of Texas System Modulation de l'expression génique par ciblage d'un petit arn endogène de promoteurs de gènes
KR20100009268A (ko) * 2008-07-18 2010-01-27 국립암센터 마이크로ｒｎａ분자를 포함하는 항암 조성물
WO2010139810A1 (fr) * 2009-06-05 2010-12-09 Febit Holding Gmbh Empreinte de micro-arn utilisée dans le diagnostic du cancer du poumon

Also Published As

Publication number Publication date
WO2013106766A2 (fr) 2013-07-18

Similar Documents

Publication Publication Date Title
MX2021010672A (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer.
PH12016501728A1 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
HK1214168A1 (zh) 通過控制血糖水平用於治療糖尿病及相關疾病的組合物、方法以及用途
MX2022004300A (es) Composicion y metodo para el diagnostico y tratamiento de enfermedades asociadas con la degeneracion de neuritas.
WO2011141823A3 (fr) Méthodes de traitement et/ou de prévention de troubles de prolifération cellulaire à l'aide d'antagonistes de il-17
WO2012083132A3 (fr) Diagnostic et traitements associés à l'inhibition de th2
MX2019006379A (es) Induccion de gen de trail de molecula pequeña en celulas normales y tumorales como una terapia anticancer.
PH12015500114A1 (en) HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF
WO2012006421A3 (fr) Diagnostic et traitement du cancer du sein
WO2013106766A3 (fr) Indications thérapeutiques du miarn-1291
MX2020011415A (es) Metodos de usar zscan4 para rejuvenecer celulas humanas.
MX2016009306A (es) Reequilibrado inmunologico epicutaneo.
WO2012012278A3 (fr) Compositions et procédés pour le traitement de troubles pathologiques associés à gpr35 et/ou au complexe gpr35-herg
WO2014205266A3 (fr) Compositions et méthodes pour la détection et le traitement du glioblastome
WO2010101793A3 (fr) Méthodes et compositions pour le diagnostic, le pronostic et le traitement du cancer
MX2018001831A (es) Biomarcadores para el tratamiento de alopecia areata.
WO2014152754A3 (fr) Méthodes de diagnostic, de sélection et de traitement de maladies et d'états causés par ou associés à des bactéries méthanogènes
WO2017011356A3 (fr) Procédés et compositions pour traiter des maladies et des états induits par des médicaments
WO2011091154A3 (fr) Utilisation d'érythrocytes humains dans la prévention et le traitement de la dissémination et de la croissance du cancer
MX2016004212A (es) Inhibidor de tor cinasa en la prevencion o tratamiento de cancer caracterizado por mutaciones genicas.
MX2015006096A (es) Leucocitos como celulas de administracion para imagen y terapia de enfermedad.
WO2012078648A3 (fr) Nouvelle méthode de diagnostic et de pronostic du cancer et prédiction de la réponse à une thérapie
WO2012129395A3 (fr) Diagnostic et traitement du cancer de la prostate
MX358072B (es) Composiciones tópicas que comprenden diaminooxidasa para el tratamiento o la prevención de enfermedades asociadas a un nivel de histamina elevada que involucran un aumento del dolor.
UA100955C2 (ru) Производные оксазина и их применение в лечении неврологических расстройств

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13736279

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13736279

Country of ref document: EP

Kind code of ref document: A2